<DOC>
	<DOCNO>NCT00329420</DOCNO>
	<brief_summary>This 26-week extension study evaluate efficacy safety certolizumab pegol administer subcutaneously every 4 week ( dosed Weeks 16 , 20 , 24 , 28 32 ) subject active Crohn 's disease clinical response Week 6 induction therapy 6-week double-blind main study , C87037 ( NCT00291668 ) , subsequently show clinical response Week 14 repeat induction therapy ( dosed Weeks 8 , 10 12 ) extension study .</brief_summary>
	<brief_title>Maintenance Study Including Re-induction Therapy Patients Who Did Not Show Clinical Effect Study C87037 ( NCT00291668 )</brief_title>
	<detailed_description>This study open-label extension study follow 6-week double-blind main study C87037 ( NCT00291668 ) . All 'Week ' number quote relative start double-blind main study . The first visit extension study Week 8 , final efficacy assessment extension study , 26 week later , Week 34 .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects give write informed consent show clinical efficacy Week 6 doubleblind main study ( NCT00291668 ) [ reduction Crohn 's Disease Activity Index ( CDAI ) score ≥100 point Week 0 , remission ( CDAI ≤150 ) ] Subjects experienced aggravation Crohn 's Disease doubleblind main study ( NCT00291668 ) require treatment change</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>CZP</keyword>
</DOC>